Denovo In-Licenses Lundbeck's Idalopirdine for Alzheimer's Disease and Other Indications
- Denovo has licensed the global rights for idalopirdine including all rights to develop- manufacture and commercialize idalopirdine for all indications. Lundbeck gets an option to reacquire idalopirdine.
- If Lundbeck exercise the option- both the companies will share rights of the product in China and if not- Denovo will retain all global rights to the product
- Idalopirdine (DB109) is an oral antagonist of the serotonin (5-HT6) receptor and is hypothesized to be involved in AD- schizophrenia- and other indications. The therapy is currently being evaluated in multiple studies encompassing 2500+ subjects
| Ref: PRNewswire | Image: PR Newswire
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at email@example.com